Envestnet Asset Management Inc. Has $104.28 Million Holdings in STERIS plc (NYSE:STE)

Envestnet Asset Management Inc. lessened its stake in STERIS plc (NYSE:STE - Free Report) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 460,080 shares of the medical equipment provider's stock after selling 6,188 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.47% of STERIS worth $104,277,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in STE. Select Equity Group L.P. boosted its holdings in shares of STERIS by 165.3% in the 4th quarter. Select Equity Group L.P. now owns 2,599,730 shares of the medical equipment provider's stock valued at $534,400,000 after buying an additional 1,619,796 shares during the last quarter. Norges Bank acquired a new stake in STERIS during the 4th quarter valued at $238,836,000. GAMMA Investing LLC lifted its holdings in STERIS by 35,759.9% during the 1st quarter. GAMMA Investing LLC now owns 410,237 shares of the medical equipment provider's stock valued at $92,980,000 after purchasing an additional 409,093 shares during the last quarter. Franklin Resources Inc. lifted its holdings in STERIS by 45.1% during the 4th quarter. Franklin Resources Inc. now owns 1,216,821 shares of the medical equipment provider's stock valued at $250,130,000 after purchasing an additional 378,252 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in STERIS by 4,534.6% during the 4th quarter. Wellington Management Group LLP now owns 219,032 shares of the medical equipment provider's stock valued at $45,024,000 after purchasing an additional 214,306 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.

Insiders Place Their Bets

In other STERIS news, CEO Daniel A. Carestio sold 17,626 shares of STERIS stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $242.56, for a total value of $4,275,362.56. Following the transaction, the chief executive officer owned 51,385 shares in the company, valued at $12,463,945.60. The trade was a 25.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Cary L. Majors sold 12,828 shares of STERIS stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $250.08, for a total value of $3,208,026.24. Following the completion of the transaction, the senior vice president owned 11,372 shares in the company, valued at approximately $2,843,909.76. This represents a 53.01% decrease in their position. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by company insiders.

STERIS Stock Down 0.5%

Shares of NYSE STE opened at $231.41 on Thursday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.39 and a current ratio of 1.96. STERIS plc has a 52 week low of $200.98 and a 52 week high of $252.79. The stock has a market capitalization of $22.76 billion, a P/E ratio of 37.32 and a beta of 0.92. The stock's fifty day moving average is $238.33 and its 200 day moving average is $225.60.

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.15. STERIS had a return on equity of 14.21% and a net margin of 11.26%. The company had revenue of $1.48 billion for the quarter, compared to analysts' expectations of $1.47 billion. During the same quarter last year, the business earned $2.58 earnings per share. STERIS's revenue was up 5.7% on a year-over-year basis. Sell-side analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 26th. Investors of record on Tuesday, June 10th were given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date of this dividend was Tuesday, June 10th. STERIS's payout ratio is currently 36.77%.

Analyst Upgrades and Downgrades

STE has been the subject of several research reports. Citigroup reaffirmed an "outperform" rating on shares of STERIS in a report on Friday, May 16th. Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a report on Monday, April 7th. JMP Securities raised their price target on STERIS from $265.00 to $280.00 and gave the company a "market outperform" rating in a report on Friday, May 16th. Morgan Stanley raised their price target on STERIS from $240.00 to $260.00 and gave the company an "equal weight" rating in a report on Monday, May 19th. Finally, Stephens reissued an "overweight" rating and set a $250.00 target price on shares of STERIS in a report on Thursday, May 15th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $263.83.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.